DE69940364D1 - Fab Fragmentbibliotheken und Verfahren für deren Verwendung - Google Patents

Fab Fragmentbibliotheken und Verfahren für deren Verwendung

Info

Publication number
DE69940364D1
DE69940364D1 DE69940364T DE69940364T DE69940364D1 DE 69940364 D1 DE69940364 D1 DE 69940364D1 DE 69940364 T DE69940364 T DE 69940364T DE 69940364 T DE69940364 T DE 69940364T DE 69940364 D1 DE69940364 D1 DE 69940364D1
Authority
DE
Germany
Prior art keywords
methods
fab fragment
fragment libraries
fab
libraries
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69940364T
Other languages
English (en)
Inventor
Hendricus Renerus J Hoogenboom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dyax Corp
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Application granted granted Critical
Publication of DE69940364D1 publication Critical patent/DE69940364D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
DE69940364T 1999-05-18 1999-05-18 Fab Fragmentbibliotheken und Verfahren für deren Verwendung Expired - Lifetime DE69940364D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99201558A EP1054018B1 (de) 1999-05-18 1999-05-18 Fab Fragmentbibliotheken und Verfahren für deren Verwendung

Publications (1)

Publication Number Publication Date
DE69940364D1 true DE69940364D1 (de) 2009-03-19

Family

ID=8240210

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69940364T Expired - Lifetime DE69940364D1 (de) 1999-05-18 1999-05-18 Fab Fragmentbibliotheken und Verfahren für deren Verwendung

Country Status (11)

Country Link
EP (2) EP2067788B1 (de)
JP (3) JP4741086B2 (de)
AT (1) ATE421976T1 (de)
AU (1) AU780145B2 (de)
CA (1) CA2372582C (de)
DE (1) DE69940364D1 (de)
DK (2) DK1054018T3 (de)
ES (2) ES2321568T3 (de)
HK (1) HK1134303A1 (de)
PT (2) PT2067788E (de)
WO (1) WO2000070023A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE481109T1 (de) 2001-10-16 2010-10-15 Us Gov Health & Human Serv Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werden
EP1504034B1 (de) 2002-05-06 2012-12-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identifikation neuer breitkreuzreaktiver hiv-1-neutralisierender humaner monoklonaler antikörper
CA2484930A1 (en) 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
US20040072262A1 (en) * 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
ES2360291T3 (es) 2003-03-07 2011-06-02 New England Medical Center Hospitals, Inc. TRATAMIENTO DE ENFERMEDADES POR DEPOSICIÓN DE IgA1.
US7157562B1 (en) * 2003-04-14 2007-01-02 The United States Of America As Represented By The Secretary Of The Army Bioprocess for the production of recombinant anti-botulinum toxin antibody
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
WO2005059176A1 (en) * 2003-12-15 2005-06-30 Institut Pasteur Repertoire determination of a lymphocyte b population
CA2554054C (en) 2004-01-20 2013-06-04 Merus B.V. Mixtures of binding proteins
WO2005069970A2 (en) 2004-01-20 2005-08-04 Kalobios, Inc. Antibody specificity transfer using minimal essential binding determinants
WO2005090407A1 (en) 2004-03-19 2005-09-29 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP1707628B1 (de) * 2005-03-30 2009-11-11 Sekisui Chemical Co., Ltd. Verfahren zur Produktion von rekombinanten polyklonalen Immunglobulinen
CA2664681C (en) 2006-10-02 2020-07-07 Sea Lane Biotechnologies, Llc Design and construction of diverse synthetic peptide and polypeptide libraries
CN101126760B (zh) * 2007-01-17 2011-11-16 江苏省人民医院 全人源抗卵泡刺激素β单链抗体筛选方法及其用途
WO2011102517A1 (ja) * 2010-02-19 2011-08-25 独立行政法人科学技術振興機構 抗ウイルス剤、抗体酵素、プライマーセット、ポリヌクレオチドの製造方法、および、ポリペプチドの製造方法
EP3103810A3 (de) 2011-04-21 2017-03-08 Garvan Institute of Medical Research Modifizierte moleküle mit variablen domänen sowie herstellungs- und verwendungsverfahren dafür
KR102096534B1 (ko) 2011-09-28 2020-04-03 에라 바이오테크, 에스.에이. 분할된 인테인 및 그의 이용
JP6393255B2 (ja) 2012-04-20 2018-09-19 メルス ナムローゼ フェンノートシャップ ヘテロ二量体のＩｇＧ様分子を生産する方法、ヘテロ二量体のＩｇＧ様分子、ヘテロ二量体の抗体、組み換え宿主細胞、医薬組成物、宿主細胞を作成する方法、および培養物
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP2883883A1 (de) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutische Ziele und Mittel zur Behandlung von ischämiebedingten Reperfusionsschäden
HUE054435T2 (hu) 2015-04-06 2021-09-28 Subdomain Llc De novo kötõdomént tartalmazó polipeptidek és alkalmazásaik
US11549119B2 (en) 2016-04-06 2023-01-10 Zumutor Biologics, Inc. Vectors for cloning and expression of proteins, methods and applications thereof
CN110291402B (zh) 2016-06-27 2023-09-01 朱诺治疗学股份有限公司 鉴定肽表位的方法、结合此类表位的分子和相关用途
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
WO2018192974A1 (en) 2017-04-18 2018-10-25 Université Libre de Bruxelles Biomarkers and targets for proliferative diseases
WO2019089982A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
BR112020009136A2 (pt) 2017-11-14 2020-10-13 Arcellx, Inc. polipeptídeos que contêm domínio d e usos dos mesmos
AU2019237215B2 (en) 2018-03-23 2023-11-02 Université Libre de Bruxelles Wnt signaling agonist molecules
US10954508B2 (en) 2018-07-08 2021-03-23 Specifica Inc. Antibody libraries with maximized antibody developability characteristics

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4518564A (en) 1983-10-03 1985-05-21 Jeneric Industries, Inc. Gallium and silver free, palladium based dental alloys for porcelain-fused-to-metal restorations
US4798885A (en) 1986-02-07 1989-01-17 Genentech, Inc. Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2057923A1 (en) 1989-05-16 1990-11-17 William D. Huse Co-expression of heteromeric receptors
ATE174058T1 (de) 1989-11-06 1998-12-15 Cell Genesys Inc Herstellung von proteinen mittels homologer rekombination
US5126323A (en) 1989-11-16 1992-06-30 Genetics Institute, Inc. Homogeneous purified k-fgf and compositions containing the same
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
DE4005633A1 (de) 1990-02-22 1991-08-29 Schuetz Werke Gmbh Co Kg Palettenbehaelter
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3672306B2 (ja) * 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート ファージミドを使用するヘテロ二量体受容体ライブラリー
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
PT663953E (pt) * 1992-09-04 2002-05-31 Scripps Research Inst Fagemideos que co-expressam um receptor de superficie e uma proteina heterologa de superficie
AU676582B2 (en) 1993-05-28 1997-03-13 Baylor College Of Medicine Method and apparatus for desorption and ionization of analytes
DK0716610T3 (da) 1993-08-26 2006-09-04 Genetics Inst Llc Humane knogle-morfogenetiske proteiner til anvendelse ved neural regenerering
AU689184B2 (en) 1993-12-07 1998-03-26 Genetics Institute, Llc BMP-12, BMP-13 and tendon-inducing compositions thereof

Also Published As

Publication number Publication date
JP5159841B2 (ja) 2013-03-13
ATE421976T1 (de) 2009-02-15
DK2067788T3 (da) 2015-10-19
HK1134303A1 (en) 2010-04-23
AU780145B2 (en) 2005-03-03
ES2549440T3 (es) 2015-10-28
PT1054018E (pt) 2009-02-16
EP1054018B1 (de) 2009-01-28
AU5142200A (en) 2000-12-05
WO2000070023A1 (en) 2000-11-23
CA2372582C (en) 2013-08-13
DK1054018T3 (da) 2009-05-18
EP2067788B1 (de) 2015-07-22
EP2067788A3 (de) 2010-04-21
PT2067788E (pt) 2015-10-29
WO2000070023A9 (en) 2002-01-17
EP1054018A1 (de) 2000-11-22
JP2002543830A (ja) 2002-12-24
JP2013078315A (ja) 2013-05-02
JP4741086B2 (ja) 2011-08-03
EP2067788A2 (de) 2009-06-10
CA2372582A1 (en) 2000-11-23
ES2321568T3 (es) 2009-06-08
JP2010273689A (ja) 2010-12-09

Similar Documents

Publication Publication Date Title
DE69940364D1 (de) Fab Fragmentbibliotheken und Verfahren für deren Verwendung
NO2006008I2 (no) Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
DK0933082T3 (da) Fremgangsmåde til manipulation af celledifferentiering
NZ334226A (en) Humanized immunoglobulin reactive with alpha 4 beta 7 integrin
ATE509955T1 (de) Humanisierte kollagen-antikörper und damit verbundene verfahren
ATE283926T1 (de) Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
CY1111966T1 (el) Αντισωματα που δεσμευονται με κυτταροσυνδετο ca 125/0722ρ και μεθοδοι χρησεις αυτων
DE69417417D1 (de) Monoklonale antikörper gegen den alpha-pdgf-rezeptor und deren verwendungen
WO2005026209A3 (en) Monoclonal antibodies against hmgb1
TW200516083A (en) Methods for making dual specificity antibodies
CY1108663T1 (el) Αναστολεις της ενεργοποιησης συμπληρωματος
ES2173130T3 (es) Metodo de fijacion de material al peptido beta-amiloide.
WO2003087340A3 (en) Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
DK0868427T3 (da) Fremgangsmåder til at idenficere forbindelser, der binder til et mål
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
ATE312622T1 (de) Verwendung von anti-hbp antikörper zur inhibierung der freisetzung von bradykinin
NO20004251D0 (no) Humaniserte anti-CEA monoklonale antistoffer med høy affinitet
ATE229037T1 (de) Monoklonaler antikörper gegen denthrombin- antithrombin iii-komplex und dessen verwendung in immunoassays
IL139571A0 (en) A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same
FR2710068B1 (fr) Dérivés de nucléosides, procédés de fabrication de ces dérivés de nucléosides et anticorps polyclonaux et monoclonaux spécifiques de ces dérivés.
Nilson The bacterial cell wall molecules protein G and protein L: Characterization and use of their immunoglobulin binding properties.
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk
CY1116268T1 (el) Αντισωματα που δεσμευονται με κυτταροσυνδετο ca 125/0772ρ και μεθοδοι χρησεις αυτων
BR1100555B1 (pt) anticorpos monoclonais humanizados.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition